Epigenetic silencing of Bim transcription by Spi-1/PU.1 promotes apoptosis resistance in leukaemia

Cell Death and Differentiation

Volumn 20, Issue 9, 2013, Pages 1268-1278

  Ridinger Saison, M ^a,b   Evanno, E ^a,b   Gallais, I ^a,b   Rimmele P ^a,b,c   Selimoglu Buet, D ^a,b,d   Sapharikas, E ^a,b,e   Moreau Gachelin, F ^a,b   Guillouf, C ^a,b  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e INSTITUT COCHIN   (France)

Author keywords

apoptosis; epigenetic regulation; leukaemia; Spi 1 PU.1 oncogene; transcription factor

Indexed keywords

BMI1 PROTEIN; HISTONE H3; HISTONE METHYLTRANSFERASE; LENTIVIRUS VECTOR; POLYCOMB GROUP PROTEIN; POLYCOMB GROUP PROTEIN SUZ12; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN MCL 1; SMALL UNTRANSLATED RNA; TRANSCRIPTION FACTOR PU 1; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CHROMATIN; DNA BINDING; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; GENE INTERACTION; GENE REPRESSION; GENE SILENCING; IN VITRO STUDY; LEUKEMIA; MARKER GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SITE DIRECTED MUTAGENESIS;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BINDING SITES; CELL DIFFERENTIATION; CELL LINE; DNA METHYLATION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; LEUKEMIA, MYELOID, ACUTE; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; MITOCHONDRIA; MULTIPROTEIN COMPLEXES; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 84882278037     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.88     Document Type: Article

References (55)

1. Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008; 22: 915-931.
2. Visconte V, Makishima H, Maciejewski JP, Tiu RV. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia 2012; 26: 2447-2454.
3. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12: 599-612.
4. Kosmider O, Denis N, Lacout C, Vainchenker W, Dubreuil P, Moreau-Gachelin F. Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice. Cancer Cell 2005; 8: 467-478.
5. Guillouf C, Gallais I, Moreau-Gachelin F. Spi-1/PU.1 oncoprotein affects splicing decisions in a promoter binding-dependent manner. J Biol Chem 2006; 281: 19145-19155.
6. Moreau-Gachelin F, Wendling F, Molina T, Denis N, Titeux M, Grimber G et al. Spi-1/PU.1 transgenic mice develop multistep erythroleukemias. Mol Cell Biol 1996; 16: 2453-2463.
7. Rimmele P, Komatsu J, Hupe P, Roulin C, Barillot E, Dutreix M et al. Spi-1/PU.1 oncogene accelerates DNA replication fork elongation and promotes genetic instability in the absence of DNA breakage. Cancer Res 2010; 70: 6757-6766.
8. Rimmele P, Kosmider O, Mayeux P, Moreau-Gachelin F, Guillouf C. Spi-1/PU.1 participates in erythroleukemogenesis by inhibiting apoptosis in cooperation with Epo signaling and by blocking erythroid differentiation. Blood 2007; 109: 3007-3014.
9. Buet D, Gallais I, Lauret E, Denis N, Lombard B, Guillonneau F et al. Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia. Blood 2012; 119: 4228-4241.
10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
11. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010; 37: 299-310.
12. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
13. Zivny J, Klener P Jr., Pytlik R, Andera L. The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies. Curr Pharm Des 2010; 16: 11-33.
14. Hsu YT, Youle RJ. Nonionic detergents induce dimerization among members of the Bcl-2 family. J Biol Chem 1997; 272: 13829-13834.
15. Yamaguchi H, Wang HG. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 2001; 20: 7779-7786.
16. Ridinger-Saison M, Boeva V, Rimmele P, Kulakovskiy I, Gallais I, Levavasseur B et al. Spi-1/PU.1 activates transcription through clustered DNA occupancy in erythroleukemia. Nucleic Acids Res 2012; 40: 8927-8941.
17. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.
18. Bouillet P, Zhang LC, Huang DC, Webb GC, Bottema CD, Shore P et al. Gene structure alternative splicing, and chromosomal localization of pro-apoptotic Bcl-2 relative Bim. Mamm Genome 2001; 12: 163-168.
19. Liu Y, Pop R, Sadegh C, Brugnara C, Haase VH, Socolovsky M. Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. Blood 2006; 108: 123-133.
20. Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, Lodish HF. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 2001; 98: 3261-3273.
21. Terszowski G, Waskow C, Conradt P, Lenze D, Koenigsmann J, Carstanjen D et al. Prospective isolation and global gene expression analysis of the erythrocyte colony-forming unit (CFU-E). Blood 2005; 105: 1937-1945.
22. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365.
23. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403.
24. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17: 525-535.
25. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294-1305.
26. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856-859.
27. Matsui H, Asou H, Inaba T. Cytokines direct the regulation of Bim mRNA stability by heat-shock cognate protein 70. Mol Cell 2007; 25: 99-112.
28. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, Allday MJ. Epstein-Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathogen 2009; 5: e1000492.
29. San Jose-Eneriz E, Agirre X, Jimenez-Velasco A, Cordeu L, Martin V, Arqueros V et al. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer 2009; 45: 1877-1889.
30. Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY, Yu Q. Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ 2010; 17: 801-810.
31. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, Siebert R, Climent J, Fresquet V et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 2007; 109: 271-280.
32. Richter-Larrea JA, Robles EF, Fresquet V, Beltran E, Rullan AJ, Agirre X et al. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 2010; 116: 2531-2542.
33. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011; 469: 343-349.
34. Leber B, Lin J, Andrews DW. Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis 2007; 12: 897-911.
35. Llambi F, Moldoveanu T, Tait SW, Bouchier-Hayes L, Temirov J, McCormick LL et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell 2011; 44: 517-531.
36. Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J 2011; 30: 3667-3683.
37. Yu M, Riva L, Xie H, Schindler Y, Moran TB, Cheng Y et al. Insights into GATA-1-mediated gene activation versus repression via genome-wide chromatin occupancy analysis. Mol Cell 2009; 36: 682-695.
38. Abutin RM, Chen J, Lung TK, Lloyd JA, Sawyer ST, Harada H. Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells. Exp Hematol 2009; 37: 151-158.
39. Yu M, Mazor T, Huang H, Huang HT, Kathrein KL, Woo AJ et al. Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. Mol Cell 2012; 45: 330-343.
40. van Haaften G, Agami R. Tumorigenicity of the miR-17-92 cluster distilled. Genes Dev 2010; 24: 1-4.
41. Kayali S, Giraud G, Morle F, Guyot B. Spi-1 Fli-1 and Fli-3 (miR-17-92) oncogenes contribute to a single oncogenic network controlling cell proliferation in friend erythroleukemia. PLoS One 2012; 7: e46799.
42. Pospisil V, Vargova K, Kokavec J, Rybarova J, Savvulidi F, Jonasova A et al. Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation. EMBO J 2011; 30: 4450-4464.
43. Ghisletti S, Barozzi I, Mietton F, Polletti S, De Santa F, Venturini E et al. Identification and characterization of enhancers controlling the inflammatory gene expression program in macrophages. Immunity 2010; 32: 317-328.
44. Stopka T, Amanatullah DF, Papetti M. Skoultchi AI. PU.1 inhibits the erythroid program by binding to GATA-1 on DNA and creating a repressive chromatin structure. EMBO J 2005; 24: 3712-3723.
45. Suzuki M, Yamada T, Kihara-Negishi F, Sakurai T, Oikawa T. Direct association between PU.1 and MeCP2 that recruits mSin3A-HDAC complex for PU.1-mediated transcriptional repression. Oncogene 2003; 22: 8688-8698.
46. Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009; 10: 697-708.
47. Bouillet P, Cory S, Zhang LC, Strasser A, Adams JM. Degenerative disorders caused by Bcl-2 deficiency prevented by loss of its BH3-only antagonist Bim. Dev Cell 2001; 1: 645-653.
48. Villa R, Pasini D, Gutierrez A, Morey L, Occhionorelli M, Vire E et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 2007; 11: 513-525.
49. Boukarabila H, Saurin AJ, Batsche E, Mossadegh N, van Lohuizen M, Otte AP et al. The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev 2009; 23: 1195-1206.
50. Ku M, Koche RP, Rheinbay E, Mendenhall EM, Endoh M, Mikkelsen TS et al. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet 2008; 4: e1000242.
51. Kanhere A, Viiri K, Araujo CC, Rasaiyaah J, Bouwman RD, Whyte WA et al. Short RNAs are transcribed from repressed polycomb target genes and interact with polycomb repressive complex-2. Mol Cell 2010; 38: 675-688.
52. Zhao J, Sun BK, Erwin JA, Song JJ, Lee JT. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science 2008; 322: 750-756.
53. Hallier M, Tavitian A, Moreau-Gachelin F. The transcription factor Spi-1/PU.1 binds RNA and interferes with the RNA-binding protein p54nrb. J Biol Chem 1996; 271: 11177-11181.
54. Martin-Perez D, Piris MA, Sanchez-Beato M. Polycomb proteins in hematologic malignancies. Blood 2010; 116: 5465-5475.
55. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010; 7: 299-313.